Use of lymphokines in treatment of experimental intra-abdominal abscess caused by Bacteroides fragilis
- PMID: 3044996
- PMCID: PMC259574
- DOI: 10.1128/iai.56.9.2369-2372.1988
Use of lymphokines in treatment of experimental intra-abdominal abscess caused by Bacteroides fragilis
Abstract
The role of cell-free soluble factors (lymphokines) derived from mitogen-activated splenic cells of mice previously immunized against Bacteroides fragilis was evaluated in the treatment of B. fragilis intra-abdominal abscess (IAA). Neither clindamycin nor lymphokines alone were effective against an established B. fragilis IAA, but the combination of clindamycin and lymphokines decreased the abscess size and bacterial counts in the majority of animals. This suggests that the synergy of lymphokines with clindamycin effects cure of IAA caused by B. fragilis and that lymphokines might have an application as adjuncts to conventional antimicrobial therapy in this setting.
Similar articles
-
Therapeutic efficacy and pharmacokinetic properties of rifampicin in a Bacteroides fragilis intra-abdominal abscess.J Antimicrob Chemother. 1984 Dec;14(6):633-40. doi: 10.1093/jac/14.6.633. J Antimicrob Chemother. 1984. PMID: 6520063
-
In vivo efficacies of quinolones and clindamycin for treatment of infections with Bacteroides fragilis and/or Escherichia coli in mice: correlation with in vitro susceptibilities.Antimicrob Agents Chemother. 1993 May;37(5):997-1000. doi: 10.1128/AAC.37.5.997. Antimicrob Agents Chemother. 1993. PMID: 8517727 Free PMC article.
-
A soluble suppressor T cell factor protects against experimental intraabdominal abscesses.J Clin Invest. 1985 Mar;75(3):1023-7. doi: 10.1172/JCI111763. J Clin Invest. 1985. PMID: 2579976 Free PMC article.
-
In vitro susceptibility vs. in vivo efficacy of various antimicrobial agents against the Bacteroides fragilis group.Rev Infect Dis. 1991 Nov-Dec;13(6):1170-80. doi: 10.1093/clinids/13.6.1170. Rev Infect Dis. 1991. PMID: 1775850 Review.
-
Management of infection following intra-abdominal trauma.Ann Emerg Med. 1988 Jun;17(6):626-32. doi: 10.1016/s0196-0644(88)80405-0. Ann Emerg Med. 1988. PMID: 3288018 Review.
Cited by
-
Efficacy of trovafloxacin for treatment of experimental Bacteroides infection in young and senescent mice.Antimicrob Agents Chemother. 1997 Sep;41(9):1933-6. doi: 10.1128/AAC.41.9.1933. Antimicrob Agents Chemother. 1997. PMID: 9303387 Free PMC article.
-
Efficacy of telithromycin (HMR 3647) against enterococci in a mouse peritonitis model.Antimicrob Agents Chemother. 2000 Dec;44(12):3434-7. doi: 10.1128/AAC.44.12.3434-3437.2000. Antimicrob Agents Chemother. 2000. PMID: 11083653 Free PMC article.
-
Antivirulence activity of auranofin against vancomycin-resistant enterococci: in vitro and in vivo studies.Int J Antimicrob Agents. 2020 Mar;55(3):105828. doi: 10.1016/j.ijantimicag.2019.10.009. Epub 2019 Oct 26. Int J Antimicrob Agents. 2020. PMID: 31669742 Free PMC article.
-
In vivo effects of rufloxacin and ciprofloxacin on T-cell subsets and tumor necrosis factor production in mice infected with Bacteroides fragilis.Antimicrob Agents Chemother. 1993 Aug;37(8):1711-2. doi: 10.1128/AAC.37.8.1711. Antimicrob Agents Chemother. 1993. PMID: 8215290 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical